NICE amends ranibizumab guidance

NICE has overturned its original decision to reject the VEGF-targeting antibody ranibizumab (Lucentis) in the treatment of diabetic macular oedema.

Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY
Ranibizumab is also recommended by NICE for the treatment of wet age-related macular degeneration | SCIENCE PHOTO LIBRARY

In a review of its 2011 guidance, NICE has ruled that ranibizumab can be considered for the treatment of visual impairment due to diabetic macular oedema, providing the eye has a central retinal thickness of 400 micrometers or more at the start of treatment.

The NICE recommendations are made on the proviso that the manufacturer provides ranibizumab with the discount agreed in the patient access scheme (as revised in 2012).

In addition to the revised patient access scheme, the decision was based on an updated clinical analysis of ranibizumab submitted by the manufacturer.

NICE guidance on ranibizumab in diabetic macular oedema

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more